Powered by

OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer

Nov 19, 2018 - GlobeNewswire

The trial, sponsored and conducted by oncology group GERCOR, will be supported by Bristol-Myers Squibb and OSE ImmunotherapeuticsPancreatic cancer is an indication with significant unmet need and represents an important new opportunity for Tedopi® clinical developmentOpening of Phase 2 trial sites scheduled for early 2019

NANTES, France, Nov. 20, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced that the French National Agency for Medi...